Ikerbasque Research Fellow Ramón y Cajal (RyC) Programme
0000-0001-6906-6065Marco Piva obtained his BSc in Biotecnology from the University of Bologna and continued his scientific pursuits by completing his PhD in Biochemistry and Molecular Biology from the University of the Basque Country (UPV/EHU) and CIC bioGUNE, Spain.
In 2014, Dr. Piva joined the laboratory Prof. Roger S. Lo at the University of California Los Angeles (UCLA) (USA). In his postdoctoral research he focused on the study of the mechanism of drug resistance in melanoma.
In 2021, Dr. Piva became a Ramón y Cajal and Ikerbasque Research Fellow (2019) in the Cancer Cell Signaling and Metabolism Lab at CIC bioGUNE and he currently holds the position of Emerging Scientist. His primary research interests focus on understanding how the immune compartment can modulate tumor aggressiveness and progression and alter response and resistance to different therapies.
Awards & recognitions
Ramón y Cajal Fellow and Ikerbasque Research Fellow (2019).
Relevant publications
Wang, Y., Liu, S., Yang, Z., Algazi, A.P., Lomeli, S.H., Wang, Y., Othus, M., Hong, A., Wang, X., Randolph, C.E., Jones, A.M., Bosenberg, M.W., Byrum, S.D., Tackett, A.J., Lopez, H., Yates, C., Solit, D.B., Ribas, A., Piva, M., Moriceau, G., Lo, R.S. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell 2021, 39, 1375-1387. https://doi.org/10.1016/j.ccell.2021.07.023
Hong, A., Piva, M., Liu, S., Hugo, W., Lomeli, S.H., Zoete, V., Randolph, C.E., Yang, Z., Wang, Y., Lee, J.J., Lo, S.J., Sun, L., Vega-Crespo, A., Garcia, A.J., Shackelford, D.B., Dubinett, S.M., Scumpia, P.O., Byrum, S.D., Tackett, A.J., Donahue, T.R., Michielin, O., Holmen, S.L., Ribas, A., Moriceau, G., Lo, R.S. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discov. 2021, 11, 714-735. https://doi.org/10.1158/2159-8290.CD-20-0873
Song, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S., Qian, J., Yu, C.C., Damoiseaux, R., Kelley, M.C., Dahlman, K.B., Scumpia, P.O., Sosman, J.A., Johnson, D.B., Ribas, A., Hugo, W., Lo, R.S. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov. 2017, 7, 1248-1265. https://doi.org/10.1158/2159-8290.CD-17-0401
Latest Publications
2020
2018
2017
2016
2014
The research in the Carracedo lab is aimed at deconstructing the essential requirements of cancer cells with special emphasis on the translation of the acquired knowledge from bench to bedside. In order to define the genuine features of cancer cells, we focus on the signalling and metabolic alterations in prostate and breast cancer. Through the use of a hierarchical approach with increasing complexity, we work on cell lines and primary cultures (using cell and molecular biology technologies), mouse models of prostate cancer that are faithful to the human disease and the analysis of human specimens through the development of prospective and retrospective studies. Our work stems from the hypothesis that cancer is driven by signalling and metabolic alterations that, once identified, can be targeted for therapy. The center and our collaborator institutions offer state-of-the-art technologies (from OMICS to in vivo imaging), which allow us to build and answer our hypotheses with high level of confidence.
To address our scientific questions in cancer, the Carracedo lab has developed a series of research lines:
- Bioinformatics-based discovery. The lab takes full advantage on publicly available human prostate and breast cancer datasets in order to identify candidate genes to contribute to cancer pathogenesis, progression and response to therapy. Best hits are then validated employing genetic mouse models, xenograft surrogate assays and the latest advances in cellular and molecular biology combined with OMICs technologies.
- Genetic mouse models as a source for the identification of novel cancer players. Genetically engineered mouse models (GEMMs) can faithfully recapitulate many aspects of human cancer. Dr. Carracedo envisions the molecular analysis of GEMMs with high throughput technologies as a mean to identify novel cancer-related genes. These hits are then validated through the analysis of human cancer specimens and cellular and molecular biology approaches.
- Multi-OMICs analysis for non-invasive biomarker identification. Biofluids are the perfect source for cancer biomarkers that can inform about the presence or features of cancer. The lab has undertaken a biomarker discovery approach by applying the latest OMICs technologies to biofluid specimens from well-annotated prostate cancer patients, in order to define better molecules that inform about this disease.
-
Group Leader
Arkaitz Carracedo
ERC Consolidator Grant - Ikerbasque Research Professor Associate Principal Investigator -
Edurne Berra
Emerging Scientist -
Isabel Mendizabal
Ikerbasque Research Fellow IKERBASQUE RESEARCH FELLOW -
Amaia Ercilla Eguiarte
Ikerbasque Research Fellow - Juan de la Cierva Fellow -
Oihana Iriondo Martinez de Zuazo
Ikerbasque Research Fellow RESEARCH ASSISTANT -
Amaia Zabala Letona
AECC Researcher -
Natalia Martín Martín
POSTDOCTORAL RESEARCHER -
Laura Bozal Basterra
-
Mikel Pujana Vaquerizo
-
Jaione Auzmendi Iriarte
-
Blanca Calle Ciborro
TECHNICIANS / DOCTORAL CANDIDATES -
Adrián Vicente Barrueco
-
María Ponce Rodríguez
-
Ianire Astobiza
-
Kathrin Keim
-
Saioa García Longarte
-
Victoria Cid I Centelles
-
Maria Camila Salazar Palacio
-
Uxue Lazcano Dobao
AECC Predoctoral Fellow -
Onintza Carlevaris
-
Encarnación Pérez Andrés
-
Maider Fagoaga Eugui
-
Jon Corres Mendizabal
-
Belén Martínez La Osa
-
Irati Aguirre Vicente
-
Mikel Arana Castañares
Members
Latest Publications
A class I PI3K signalling network regulates primary cilia disassembly in normal physiology and disease
Conduit, SE; Pearce, W; Bhamra, A; Bilanges, B; Bozal-Basterra, L; Foukas, LC; Cobbaut, M; Castillo, SD; Danesh, MA; Adil, M; Carracedo, A; Graupera, M; McDonald, NQ; Parker, PJ; Cutillas, PR; ...
NATURE COMMUNICATIONS
2024-08-21
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics
Gil-Redondo, R; Conde, R; Bruzzone, C; Seco, ML; Bizkarguenaga, M; González-Valle, B; de Diego, A; Lain, A; Habisch, H; Haudum, C; Verheyen, N; Obermayer-Pietsch, B; Margarita, S; Pelusi, S; ...
CARDIOVASCULAR DIABETOLOGY
2024-07-24
Metastatic hormone-naïve prostate cancer: a distinct biological entity
Corres-Mendizabal, J; Zacchi, F; Martín-Martín, N; Mateo, J; Carracedo, A;
TRENDS IN CANCER
2024-07-23
The PP2A regulator IER5L supports prostate cancer progression
Crespo, JR; Martín-Martín, N; Garcia-Longarte, S; Corres-Mendizabal, J; Carlevaris, O; Astobiza, I; Zabala-Letona, A; Guiu, M; Azkargorta, M; Gonzalez-Lopez, M; Macías-Cámara, N; Doan, P; Elortza, ...
CELL DEATH & DISEASE
2024-07-18
Metabolic adaptations in prostate cancer
Pujana-Vaquerizo, M; Bozal-Basterra, L; Carracedo, A;
BRITISH JOURNAL OF CANCER
2024-07-05
SERS analysis of cancer cell- secreted purines reveals a unique paracrine crosstalk in MTAP- deficient tumors
Valera, PS; Plou, J; Garcia, I; Astobiza, I; Viera, C; Aransay, AM; Martin, JE; Sasselli, IR; Carracedo, A; Liz-Marzan, LM;
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
2023-12-26
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
Pencik, J; Philippe, C; Schlederer, M; Atas, E; Pecoraro, M; Grund-Gröchke, S; Li, W; Tracz, A; Heidegger, I; Lagger, S; Trachtová, K; Oberhuber, M; Heitzer, E; Aksoy, O; Neubauer, HA; Wingelhofer, ...
MOLECULAR CANCER
2023-08-12
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
García-Vilchez, R; Anazco-Guenkova, AM; Dietmann, S; López, J; Morón-Calvente, V; DAmbrosi, S; Nombela, P; Zamacola, K; Mendizabal, I; García-Longarte, S; Zabala-Letona, A; Astobiza, I; Fernández, ...
MOLECULAR CANCER
2023-07-29
Metabolism in the tumor cell and beyond
Carracedo, A;
MOLECULAR ONCOLOGY
2023-06-06
Machine Learning-Assisted High-Throughput SERS Classification of Cell Secretomes
Plou, J; Valera, PS; García, I; Vila-Liarte, D; Renero-Lecuna, C; Ruiz-Cabello, J; Carracedo, A; Liz-Marzán, LM;
SMALL
2023-04-12
Identifying prognostic parameters related to surgical technique in patients treated by robotic radical prostatectomy
Iriarte, AL; Viscasillas, IL; Gonzalez, SR; Martín, AS; Aparicio, DG; Olano, AU; Pérez, AC; Urzaiz, MU;
ACTAS UROLOGICAS ESPANOLAS
2023-01-01
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer
Santasusagna, S; Zhu, S; Jawalagatti, V; Carceles-Cordon, M; Ertel, A; Garcia-Longarte, S; Song, WM; Fujiwara, N; Li, P; Mendizabal, I; Petrylak, DP; Kelly, WK; Reddy, EP; Wang, L; Schiewer, ...
CANCER DISCOVERY
2023-01-01
CiberAMP: An R Package to Identify Differential mRNA Expression Linked to Somatic Copy Number Variations in Cancer Datasets
Caloto, R; Lorenzo-Martín, LF; Quesada, V; Carracedo, A; Bustelo, XR;
BIOLOGY-BASEL
2022-10-01
RAD51 is a druggable target that sustains replication fork progression upon DNA replication stress
Feu, S; Unzueta, F; Ercilla, A; Pérez-Venteo, A; Jaumot, M; Agell, N;
PLOS ONE
2022-08-15
Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma
Davidson, SM; Schmidt, DR; Heyman, JE; Brien, JPO; Liu, AC; Israelsen, WJ; Dayton, TL; Sehgal, R; Bronson, RT; Freinkman, E; Mak, HH; Fanelli, GN; Malstrom, S; Bellinger, G; Carracedo, A; Pandolfi, ...
CANCER RESEARCH
2022-07-01
Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
Arruabarrena-Aristorena, A; Toska, E;
FRONTIERS IN ONCOLOGY
2022-06-14
Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen
Rodríguez-Agudo, R; Goikoetxea-Usandizaga, N; Serrano-Maciá, M; Fernández-Tussy, P; Fernández-Ramos, D; Lachiondo-Ortega, S; González-Recio, I; Gil-Pitarch, C; Mercado-Gómez, M; Morán, L; Bizkarguenaga, ...
ANTIOXIDANTS
2022-05-01
High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML
Aldaz, P; Martín-Martín, N; Saenz-Antoñanzas, A; Carrasco-Garcia, E; Alvarez-Satta, M; Elúa-Pinin, A; Pollard, SM; Lawrie, CH; Moreno-Valladares, M; Samprón, N; Hench, J; Lovell-Badge, R; Carracedo, ...
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
2022-05-01
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Araujo, AM; Abaurrea, A; Azcoaga, P; Lopez-Velazco, JI; Manzano, S; Rodriguez, J; Rezola, R; Egia-Mendikute, L; Valdés-Mora, F; Flores, JM; Jenkins, L; Pulido, L; Osorio-Querejeta, I; Fernández-Nogueira, ...
JOURNAL OF CLINICAL INVESTIGATION
2022-04-01
Angiocrine polyamine production regulates adiposity
Monelli, E; Villacampa, P; Zabala-Letona, A; Martinez-Romero, A; Llena, J; Beiroa, D; Gouveia, L; Chivite, I; Zagmutt, S; Gama-Perez, P; Osorio-Conles, O; Muixi, L; Martinez-Gonzalez, A; Castillo, ...
NATURE METABOLISM
2022-03-14